Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan-Dec;12(1):1854149.
doi: 10.1080/19420862.2020.1854149.

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Marco Tuccori  1   2 , Sara Ferraro  2 , Irma Convertino  2 , Emiliano Cappello  2 , Giulia Valdiserra  2 , Corrado Blandizzi  1   2 , Fabrizio Maggi  3 , Daniele Focosi  4
Affiliations

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Marco Tuccori et al. MAbs. 2020 Jan-Dec.

Abstract

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials. We describe the structure, mechanism of action, and ongoing trials for VIR-7831, LY-CoV555, LY-CoV016, BGB-DXP593, REGN-COV2, and CT-P59. We speculate also on the next generation of these mAbs.

Keywords: BGB-DXP593; COVID-19; CT-P59; GSK4182136; LY-CoV016; LY-CoV555; REGN-COV2; SARS-CoV-2; VIR-7831; bamlanivimab; monoclonal antibody.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Characterization of antibody-based therapies for SARS-CoV-2
See this image and copyright information in PMC

References

    1. Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D, Blandizzi C.. The impact of the COVID-19 “Infodemic” on drug-utilization behaviors: implications for pharmacovigilance. Drug Saf. 2020;43(8):699–8. doi:10.1007/s40264-020-00965-w. - DOI - PMC - PubMed
    1. Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Crit Care. 2020;24(1):331. doi:10.1186/s13054-020-03020-3. - DOI - PMC - PubMed
    1. Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, Gronenschild M, de Kruif MD, van Haren EHJ, van Kraaij T, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020;79(9):1143–51. doi:10.1136/annrheumdis-2020-218479. - DOI - PMC - PubMed
    1. Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent plasma therapy for COVID-19: state of the art. Clin Microbiol Rev. 2020;33(4). doi:10.1128/CMR.00072-20. - DOI - PMC - PubMed
    1. Focosi D, Maggi F, Mazzetti P, Pistello M. Viral infection neutralization tests: a focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy. Rev Med Virol. 2020. August. doi:10.1002/rmv.2170. - DOI - PMC - PubMed

MeSH terms